DGAP-News: Sangui BioTech International Inc. / Key word(s): Market
launch
Sangui BioTech: Laboratorios Silanes start marketing Granulox in
Mexico (news with additional features)
03.11.2014 / 11:00
=--------------------------------------------------------------------
Sangui BioTech: Laboratorios Silanes start marketing Granulox in Mexico
Applications for licensing in all Central American countries under way
Witten, Germany, November 3, 2014 - Laboratorios Silanes
(www.silanes.com.mx) commenced with the marketing of the dressing material
Granulox in Mexico on November 1, 2014, based on an exclusive agreement
with SastoMed GmbH. At the same time, Silanes has taken over the
distribution for the remaining countries of Central America and is
currently applying for the necessary certifications in the respective
individual markets. To be ready for the start of distribution, Silanes
ordered, received and paid for merchandise in the previous quarter, which
was reflected in a considerable five-digit license income by Sangui as of
30 September 2014.
Laboratorios Silanes was founded in 1943 and, with a workforce of around
700 employees, today ranks among the leading mid-sized pharmaceutical
companies of Central America and in terms of revenues occupies third place
in the league of the highest-volume suppliers of products suitable for
diabetics.
Prior to the start of the distribution, 250 sales representatives took part
in a training event which also included an in-depth presentation by Michael
Sander, Chief Executive Officer of SastoMed GmbH, the global licensee for
the sale of Granulox. The sales force was introduced to the mode of action
and the application in a series of detailed scientific and practical
presentations, and given the marketing goals and materials.
"The start to marketing by Silanes concludes intensive preliminary work
which took two years and the restructuring of our Mexico business",
explained Michael Sander. "Thanks to the support of BioMac CEO John
McArdle, we now have gained a highly professional partner in Silanes which
has the market position to leverage the public profile of Granulox locally
and to translate it into tangible success."
Antonio Lopez de Silanes, jr., the owner of Laboratorios Silanes, explained
at a national sales congress organized by his company that Granulox had the
potential for developing into a core component of the product portfolio. He
anticipates that the investments in pre-marketing and marketing will soon
pay off.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges.
Its purpose is to provide financing and access to the capital markets for
the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing@sangui.de
+++++
Additional features:
Document: http://n.equitystory.com/c/fncls.ssp?u=INYIQCXBCH
Document title: Sangui BioTech: Laboratorios Silanes start marketing
Granulox in Mexico
=--------------------------------------------------------------------
03.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
=--------------------------------------------------------------------
294618 03.11.2014
(END) Dow Jones Newswires
November 03, 2014 05:00 ET (10:00 GMT)
